Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 228 participants.

Also called NCT06226805

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 2
Enrolled
  • 228 participants (planned count) (from the registry)
Sponsor
Basking Biosciences, Inc. (from the registry)
Registry
  • NCT NCT06226805
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Australia, Canada (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06226805. Randomized; quadruple masking; primary purpose prevention. Start 2024-07-31 (actual); primary completion 2027-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)
Acronym
RAISE
Condition
Acute Ischemic Stroke
Intervention (Drug)
BB-031
Intervention (Drug)
Placebo
Lead sponsor
Basking Biosciences, Inc. (class: industry)

Record details

Record id
cardio:ct-nct06226805
Content hash
6e6c02dab033f0ad121009a3da26bb478eafc9cca4b894aace1f74ff812de7fa